Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 389 participants.

Also called NCT04988386

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 389 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04988386
  • EudraCT 2020-005643-22
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Greece, Ireland, Israel, Italy, Netherlands, New Zealand, Portugal, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04988386. Allocation not applicable; no masking; primary purpose treatment. Start 2021-10-27 (actual); primary completion 2028-04-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Acronym
AG10
Condition
Amyloid Cardiomyopathy, Transthyretin-Related
Intervention (Drug)
Acoramidis (AG10)
Lead sponsor
Eidos Therapeutics, a BridgeBio company (class: industry)

Record details

Record id
cardio:ct-nct04988386
Content hash
2cd447227c63ac94b2828a5fe9eb27d3fa9f481987c861c753ca07200967f9e9